Diabetes Devices and Drugs Market Devices

Published on December 2016 | Categories: Documents | Downloads: 42 | Comments: 0 | Views: 428
of 11
Download PDF   Embed   Report

Comments

Content

Brochure
More information from http://www.researchandmarkets.com/reports/3447242/

Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and
Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global
Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast
2013 - 2019
Description:

Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is
not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as
increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes
causes various acute and chronic life-threatening complications. This report studies the current as well as
future scenario of the diabetes diagnostic devices and drugs market globally.
The diabetes diagnostic devices and drugs market has been segmented based on devices and drugs
available for the treatment the disease. Based on device type, the market is segmented into diabetes
diagnostic devices and insulin delivery devices. Diabetes diagnostic devices include analog blood meter, test
strips, lancets and lancing devices, continuous glucose monitoring devices and others. The insulin delivery
devices segment include insulin syringes, insulin pens, insulin pumps and insulin injectors.
Based on drugs, the market is segmented into insulin derivatives, oral anti-diabetes drugs and non-insulin
injectable anti-diabetes drugs. The insulin derivatives segment is further categorized as rapid-acting, shortacting, intermediate-acting, long-acting and premixed insulin derivatives. The oral anti-diabetes drugs
segment includes various drugs classes such as sulphonylureas, meglitinides, biguanides, alpha-glucosidase
inhibitors, GPP-4 inhibitors and SGLT-2 inhibitors.
The non-insulin injectable anti-diabetes drugs segment is segmented into GLP-1 analogs and Pramlintide.
The market for these devices and drugs has been extensively analyzed based on demand for branded and
generic products in each class of drugs and devices. Rising prevalence of diabetic population across various
regions of the world, pipeline products from each class, rising preference of patients and healthcare
professionals toward technologically advanced monitoring and insulin delivery devices is driving the growth
of the diabetes diagnostic devices and drugs market.
The market size and forecasts in terms of revenue (USD million) for each of these segments have been
provided for the period 2013 to 2019, considering 2012 as the base year. The diabetes devices and drugs
market report also provides the compounded annual growth rate (CAGR) for each segment of the market for
the forecast period 2013 to 2019.
Geographically, the diabetes diagnostic devices and drugs market has been segmented into four major
regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for
each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period
2013 to 2019. The diabetes diagnostic devices and drugs market study also includes qualitative analysis of
the competitive scenario in these regions.
The market overview section of the report comprises a qualitative analysis of the overall market considering
the factors determining the market dynamics such as drivers, restraints and opportunities, along with
Porter’s five forces analysis and market attractiveness analysis. In addition, thorough analyses of various
events, which occurred in the past five years and are expected to occur during forecast period, are also
provided in the market overview section of the report. In this section, the major events, which affected the
market and are expected to affect the market are studied. Further, value chain analysis (VCA) for drugs and
devices is also provided, which highlights the major stages of the development of drugs and devices. The
entire section of market overview plays an important role in understanding the market on a global level.
The diabetes devices and drugs market report also provides a highlight of the competitive landscape of the
market wherein the market share analysis of the leading players in the diabetes devices and drugs market,
in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included
for new entrants as well as existing market players to help them establish a strong presence in the market
and accentuate market shares.

The report concludes with the profiles of major players in the diabetes devices and drugs market such as
Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson
and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd.,
GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis
International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Company Limited. Market players
are profiled based on attributes such as company overview, financial overview, business strategies adopted
by the companies to ensure sustainability and maximize profits, product portfolio and recent developments.
The global diabetes devices and drugs market is segmented into the following categories:
Global Diabetes Devices Market, by Devices
- Diabetes Monitoring and diagnostic devices
-- Analog glucose meter
-- Glucose Test strips
-- Lancets and Lancing devices
-- Continuous glucose monitoring devices
-- Others
- Insulin Delivery Devices
-- Insulin Syringes
-- Insulin Pens
-- Insulin Pumps
-- Insulin Injectors
Global Diabetes Drugs Market, by Therapy
- Insulin
-- Short-acting insulin derivatives
-- Intermediate-acting insulin derivatives
-- Long-acting insulin derivatives
-- Rapid-acting insulin derivatives
-- Premixed insulin derivatives
- Oral anti-diabetes drugs class
-- Sulphonylureas
-- Biguanides
-- Meglitinides
-- Thiazolidinediones
-- Alpha-glucosidase inhibitors
-- DPP-4 inhibitors
-- SGLT-2 inhibitors
- Non-insulin injectable anti-diabetes drugs
-- GLP-1 analogs
Global Diabetes Drugs Market, by Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)

Contents:

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research
1.3.2 Assumptions
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Diabetes Devices and Drugs Market (2012 & 2019)
2.2 Market Snapshot: Global Diabetes Devices Market (2012 & 2019)
2.3 Global Diabetes Devices Market, by Types, 2012 (USD Million)
2.4 Market Snapshot: Global Diabetes Drugs Market (2012 & 2019)
2.5 Global Diabetes Drugs Market, by Drug Therapy, 2012 (USD Million)

2.6 Competitive Analysis: Global Diabetes Devices and Drugs Market, By Geography, 2012 & 2019 (Value %)
Chapter 3 Disease Overview: Diabetes
3.1 Overview
3.2 Classification
3.3 Symptoms
3.4 Causes
3.5 Risk Factors
3.6 Chronic diseases associated with diabetes
3.7 Diagnosis
3.8 Flow Chart of Approach of Diabetes Management
3.9 Management
3.9.1 Non-medicinal aspects of diabetes management
3.9.1.1 Diet
3.9.1.2 Weight Management
3.9.1.3 Exercise
3.9.1.4 Sleep management
3.9.2 Medicinal Management
3.9.2.1 Insulin
3.9.2.2 Oral anti-diabetes drugs class
3.9.2.3 Non-insulin injectable anti-diabetes drugs
3.10 Standard Glucose levels for Diabetic Patients
Chapter 4 Market Overview
4.1 Overview
4.2 Market Drivers
4.2.1 Global rise in diabetic population expected to propel diabetes market
4.2.2 Extensive R&D activities bring turnaround changes in the diabetes market
4.2.3 Chronic diseases associated with diabetes fuels self-monitoring and insulin delivery devices market
4.2.4 Technological innovations are the market boosters
4.2.5 Pricing strategies played by key players bring strong changes in the global market
4.3 Market Restraints
4.3.1 Patent expiry depletes profit of market
4.3.2 High cost of diagnosis and treatment
4.3.3 Unfavorable reimbursement policies
4.3.4 Hard entry barriers demotivate new players to enter the market
4.4 Market Opportunities
4.4.1 Development of non-invasive diabetes diagnostic and drug delivery devices augments the market
growth
4.4.2 Strong pipeline and development of molecules from newer class of diabetes drugs provide a ladder for
growth
4.4.3 Development of new formulations of insulin offer new market leads
4.5 Porter’s Five Force Analysis of the Global Diabetes Devices Market
4.5.1 Bargaining power of suppliers
4.5.2 Bargaining power of buyers
4.5.3 Threat of substitutes
4.5.4 Threat of new entrants
4.5.5 Competitive rivalry
4.6 Porter’s Five Force Analysis of the Global Diabetes Drugs Market
4.6.1 Bargaining power of suppliers
4.6.2 Bargaining power of buyers
4.6.3 Threat of new entrants
4.6.4 Threat of substitutes
4.6.5 Competitive rivalry
4.7 Event Impact Analysis
4.7.1 Impact of positive events on diabetes devices and drugs Market
4.7.2 Impact of negative events on diabetes devices and drugs market
4.8 Value Chain Analysis for Diabetes Drugs Market
4.9 Value Chain Analysis for Diabetes Devices Market
4.10 Market Attractiveness Analysis: Global Diabetes Devices and Drugs Market, by Geography
Chapter 5 Diabetes Devices Market, by Device Types
5.1 Overview

5.1.1 Global Diabetes Devices Market Revenue, by Device Types, 2011 - 2019 (USD Million)
5.2 Glucose Monitoring and Diagnostic Devices
5.2.1 Global Glucose Monitoring and Diagnostic Devices Market Revenue, by Types, 2011 - 2019 (USD Million)
5.2.2 Lancets
5.2.2.1 Global Lancets Market Revenue, 2011 - 2019 (USD Million)
5.2.3 Analog Glucose Meter
5.2.3.1 Global Analog Glucose Meters Market Revenue, 2011 - 2019 (USD Million)
5.2.4 Glucose Test Strips
5.2.4.1 Global Glucose Test Strips Market Revenue, 2011 - 2019 (USD Million)
5.2.5 Continuous Glucose Monitoring Devices (CGM)
5.2.5.1 Global Continuous Glucose Monitoring (CGM) Devices Market Revenue, 2011 - 2019 (USD Million)
5.2.6 Others
5.2.6.1 mHealth Blood Glucose Monitors
5.2.6.2 Glycated Hemoglobin Testing Products (Hemoglobin A1c Testing Kit)
5.2.6.3 Urine Glucose/Metabolite Monitoring Strips
5.2.6.4 Global Others Devices Market Revenue, 2011 - 2019 (USD Million)
5.3 Insulin Delivery Devices
5.3.1 Global Insulin Delivery Devices Market Revenue, by Types, 2011 - 2019 (USD Million)
5.3.2 Insulin Syringes
5.3.2.1 Global Insulin Syringes Market Revenue, 2011 - 2019 (USD Million)
5.3.3 Insulin Pens
5.3.3.1 Global Insulin Pens Market Revenue, 2011 - 2019 (USD Million)
5.3.4 Insulin Pumps
5.3.4.1 Global Insulin Pumps Market Revenue, 2011 - 2019 (USD Million)
5.3.5 Insulin Injectors
5.3.5.1 Global Insulin Injectors Market Revenue, 2011 - 2019 (USD Million)
Chapter 6 Global Diabetes Drugs Market, by Drug Therapy
6.1 Overview
6.1.1 Global Diabetes Drugs Market Revenue, by Drug Therapy, 2011 - 2019 (USD Million)
6.1.2 Comparative Analysis: Global Diabetes Drugs Market Revenue, by Drug Therapy, 2012 & 2019 (Value %)
6.2 Oral Anti-Diabetes Drugs (OADs)
6.2.1 Mechanism of action for different OAD Classes
6.2.2 Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
6.2.3 Comparative Analysis: Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2012 & 2019 (Value
%)
6.2.4 Sulphonylureas
6.2.4.1 Global Sulphonylureas Market Revenue, 2011 - 2019 (USD Million)
6.2.5 Meglitinides
6.2.5.1 Global Meglitinides Market Revenue, 2011 - 2019 (USD Million)
6.2.6 Biguanides
6.2.6.1 Global Biguanides Market Revenue, 2011 - 2019 (USD Million)
6.2.7 Thiazolidinediones (TZDs)
6.2.7.1 Global Thiazolidinediones Market Revenue, 2011 - 2019 (USD Million)
6.2.8 Alpha-Glucosidase Inhibitors
6.2.8.1 Global Alpha-Glucosidase Inhibitors Market Revenue, 2011 - 2019 (USD Million)
6.2.9 Gliptins or DPP-4 Inhibitors
6.2.9.1 Global DPP-4 Inhibitors Market Revenue, 2011 - 2019 (USD Million)
6.2.9.2 Pipeline Analysis
6.2.9.2.1 MK-3102 (Omarigliptin)
6.2.10 Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
6.2.10.1 Mechanism action of SGLT2 Inhibitors
6.2.10.2 Global Sodium Glucose Co-Transporter 2 Market Revenue, 2011 - 2019 (USD Million)
6.2.10.3 Pipeline Analysis
6.2.10.3.1 Ertugliflozin
6.2.10.3.2 Jardiance (Empagliflozin)
6.3 Non-Insulin Injectable Drugs
6.3.1 GLP-1 Agonists
6.3.2 Global GLP-1 Agonists Market Revenue, 2011 - 2019 (USD Million)
6.3.3 Pipeline Analysis
6.3.3.1 Dulaglutide
6.3.3.2 Semaglutide (NN9535)
6.3.3.3 LATIN T1D(NN9211)

6.3.3.4 Tanzeum (Albiglutide)
6.4 Insulin
6.4.1 Characteristics of type of Insulin
6.4.2 Global Insulin Market Revenue, by Mode of Action, 2011 - 2019 (USD Million)
6.4.3 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action, 2012 & 2019 (Value %)
6.4.4 Short-Acting Insulin
6.4.4.1 Global Short-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
6.4.5 Rapid-Acting Insulin
6.4.5.1 Global Rapid-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
6.4.5.2 Pipeline Analysis
6.4.5.2.1 Afrezza
6.4.5.2.2 NN1218 (FIAsp)
6.4.6 Long-Acting Insulin
6.4.6.1 Global Long-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
6.4.6.2 Pipeline Analysis
6.4.6.2.1 LY2605541(Novel Basal Insulin Analog)
6.4.6.2.2 LY2963016 (Long acting basal insulin)
6.4.6.2.3 MK-1293 (Sustained release insulin analog)
6.4.6.2.4 U-300 (Toujeo)
6.4.6.2.5 IDegLira (Xultophy)
6.4.7 Intermediate-Acting Insulin
6.4.7.1 Global Intermediate-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
6.4.8 Premixed Insulin
6.4.8.1 Global Premixed Insulin Market Revenue, 2011 - 2019 (USD Million)
Chapter 7 Diabetes Devices and Drugs Market Revenue, by Geography
7.1 Overview
7.1.1 Global Diabetes Devices and Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)
7.2 North America
7.2.1 North America Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
7.3 Europe
7.3.1 Europe Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
7.4 Asia-Pacific
7.4.1 Asia-Pacific Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
7.5 Rest of the World (RoW)
7.5.1 Global RoW Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
Chapter 8 Competitive Landscape
8.1 Market Share Analysis, Global Glucose Monitoring and Diagnostic Devices, by Key Players, 2012 (%)
8.1.1 Market Share Analysis, Global Glucose Montoring and Diagnostic Devices Market, 2012 (Value %)
8.2 Market Share Analysis, Global Insulin Delivery Devices, by Key Players, 2012 (%)
8.2.1 Market Share Analysis, Global Insulin Delivery Devices Market, 2012 (Value %)
8.3 Market Share Analysis, Global Diabetes Drugs, by Key Players 2012 (%)
8.3.1 Market Share Analysis, Global Diabetes Drugs Market, 2012 (Value %)
Chapter 9 Recommendations
9.1 Development of formulations that can be administered by different routes
9.2 Development of combination formulations
9.3 Focus on emerging markets
9.4 Overcoming technical incompatibilities
9.5 Development of technically innovative devices to overcome the limitations of existing devices
9.6 Development of cost-effective products
Chapter 10 Company Profiles
10.1 Abbott Laboratories, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AstraZeneca plc
10.2.1 Company Overview
10.2.2 Financial Overview

10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 B. Braun Melsungen AG
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 Bayer HealthCare AG
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Becton, Dickinson & Company
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Boehringer Ingelheim GmbH
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Development
10.7 DexCom, Inc.
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 Eli Lilly and Company
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 F. Hoffmann-La Roche Ltd.
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 GlaxoSmithKline plc
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 Johnson & Johnson
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Lupin Limited
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments

10.13 Medtronic, Inc.
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Merck & Co., Inc.
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 Novartis International AG
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments
10.16 Novo Nordisk A/S
10.16.1 Company Overview
10.16.2 Financial Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.16.5 Recent Developments
10.17 Sanofi
10.17.1 Company Overview
10.17.2 Financial Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.17.5 Recent Developments
10.18 Takeda Pharmaceutical Company Limited
10.18.1 Company Overview
10.18.2 Financial Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.18.5 Recent Development
List of Figures
FIG. 1 Diabetes Devices Market: Market Segmentation
FIG. 2 Diabetes Drugs Market: Market Segmentation
FIG. 3 Global Diabetes Devices Market, by Types, 2012 (USD Million)
FIG. 4 Global Diabetes Drugs Market, by Drug Therapy, 2012 (USD Million)
FIG. 5 Comparative Analysis: Global Diabetes Devices and Drugs Market Revenue, by Geography, 2012 &
2019 (Value %)
FIG. 6 Flow Chart of Approach of Diabetes Management
FIG. 7 Pipeline Analysis: Diabetes Drugs under pipeline studies according tophases of clinical trials: 2013
FIG. 8 Porter’s Five Force Analysis: Global Diabetes Devices Market
FIG. 9 Porter’s Five Force Analysis: Global Diabetes Drugs Market
FIG. 10 Value Chain Analysis for Diabetes Drugs Market
FIG. 11 Value Chain Analysis for Diabetes Devices Market
FIG. 12 Market Attractiveness Analysis: Global Diabetes Devices and Drugs Market, by Geography
FIG. 13 Global Lancets Market Revenue, 2011 - 2019 (USD Million)
FIG. 14 Global Analog Glucose Meters Market Revenue, 2011 - 2019 (USD Million)
FIG. 15 Global Glucose Test Strips Market Revenue, 2011 - 2019 (USD Million)
FIG. 16 Global Continuous Glucose Monitoring (CGM) Devices Market Revenue, 2011 - 2019 (USD Million)
FIG. 17 Global Others Devices Market Revenue, 2011 - 2019 (USD Million)
FIG. 18 Global Insulin Syringes Market Revenue, 2011 - 2019 (USD Million)
FIG. 19 Global Insulin Pens Market Revenue, 2011 - 2019 (USD Million)
FIG. 20 Global Insulin Pumps Market Revenue, 2011 - 2019 (USD Million)
FIG. 21 Global Insulin Injectors Market Revenue, 2011 - 2019 (USD Million)
FIG. 22 Comparative Analysis: Global Anti-Diabetes Drugs Market Revenue, by Drug Therapy, 2012 & 2019
(Value %)
FIG. 23 Mechanism of action for different OAD Classes

FIG. 24 Comparative Analysis: Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2012 & 2019 (Value
%)
FIG. 25 Global Sulphonylureas Market Revenue, 2011 - 2019 (USD Million)
FIG. 26 Global Meglitinides Market Revenue, 2011 - 2019 (USD Million)
FIG. 27 Global Biguanides Market Revenue, 2011 - 2019 (USD Million)
FIG. 28 Global Thiazolidinediones Market Revenue, 2011 - 2019 (USD Million)
FIG. 29 Global Alpha-Glucosidase Inhibitors Market Revenue, 2011 - 2019 (USD Million)
FIG. 30 Global DPP-4 Inhibitors Market Revenue, 2011 - 2019 (USD Million)
FIG. 31 Global MK-3102 Market Revenue, 2016 - 2019 (USD Million)
FIG. 32 Mechanism action of SGLT2 Inhibitors
FIG. 33 Global Sodium Glucose Co-Transporter 2 Market Revenue, 2011 - 2019 (USD Million)
FIG. 34 Global Ertugliflozin Market Revenue, 2017 - 2019 (USD Million)
FIG. 35 Global Jardiance Market Revenue, 2015 - 2019 (USD Million)
FIG. 36 Global GLP-1 Agonists Market Revenue, 2011 - 2019 (USD Million)
FIG. 37 Global Dulaglutide Market Revenue, 2015- 2019 (USD Million)
FIG. 38 Global Semaglutide Market Revenue, 2016 - 2019 (USD Million)
FIG. 39 Global LATIN T1D Market Revenue, 2016- 2019 (USD Million)
FIG. 40 Global Tanzeum Market Revenue, 2014 - 2019 (USD Million)
FIG. 41 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action 2012 & 2019 (Value %)
FIG. 42 Global Short-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
FIG. 43 Global Rapid-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
FIG. 44 Global Afrezza Market Revenue, 2015 - 2019 (USD Million)
FIG. 45 Global NN1218 Market Revenue, 2016 - 2019 (USD Million)
FIG. 46 Global Long-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
FIG. 47 Global LY2605541 Market Revenue, 2015 - 2019 (USD Million)
FIG. 48 Global LY2963016 Market Revenue, 2014 - 2019 (USD Million)
FIG. 49 Global MK-1293 Market Revenue , 2016 - 2019 (USD Million)
FIG. 50 Global U-300 Market Revenue, 2015 - 2019 (USD Million)
FIG. 51 Global IDegLira Market Revenue, 2014 - 2019 (USD Million)
FIG. 52 Global Intermediate-Acting Insulin Market Revenue, 2011 - 2019 (USD Million)
FIG. 53 Global Premixed Market Revenue, 2011 - 2019 (USD Million)
FIG. 54 North America Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
FIG. 55 Europe Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
FIG. 56 Asia-Pacific Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
FIG. 57 Rest of the World (RoW) Diabetes Devices and Drugs Market Revenue, 2011 - 2019 (USD Million)
FIG. 58 Market Share Analysis, Global Glucose Montiring and Diagnostic Devices Market, 2012 (Value %)
FIG. 59 Market Share Analysis, Global Insulin Delivery Devices Market, 2012 (Value %)
FIG. 60 Market Share Analysis, Global Diabetes Drugs Market, 2012 (Value %)
FIG. 61 Abbott Laboratories, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 62 AstraZeneca plc: Annual Revenue 2011 - 2013 (USD Million)
FIG. 63 B Braun Melsungen AG: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 64 Bayer HealthCare AG: Annual Revenue: 2011 - 2013 (USD Million)
FIG. 65 Becton Dickinson & Company: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 66 Boehringer Ingelheim GmbH: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 67 DexCom, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 68 Eli Lilly and Company: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 69 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 70 GlaxoSmithKline plc: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 71 Johnson & Johnson: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 72 Lupin Limited: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 73 Medtronic, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 74 Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 75 Novartis International AG: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 76 Novo Nordisk A/S.: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 77 Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
FIG. 78 Takeda Pharmaceutical Company Limited: Annual Revenue: 2011 - 2013 (USD Million)
List of Tables
TABLE 1 Market Snapshot: Global Diabetes Devices and Drugs Market (2012 & 2019)
TABLE 2 Market Snapshot: Global Diabetes Devices Market (2012 & 2019)
TABLE 3 Market Snapshot: Global Diabetes Drugs Market (2012 & 2019)
TABLE 4 Number of People with Diabetes (20 Years - 79 years), by Country/Territory, 2013 (Millions)
TABLE 5 Global Diabetes Devices Market Revenue, by Device Types, 2011 - 2019 (USD Million)

TABLE 6 Global Glucose Monitoring and Diagnostic Devices Market Revenue, by Types, 2011 - 2019 (USD
Million)
TABLE 7 Global Insulin Delivery Devices Market Revenue, by Types, 2011 - 2019 (USD Million)
TABLE 8 Global Diabetes Drugs Market Revenue, by Drug Therapy, 2011 - 2019 (USD Million)
TABLE 9 Global Oral Anti-Diabetes Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
TABLE 10 Global Insulin Market Revenue, by Mode of Action, 2011 - 2019 (USD Million)
TABLE 11 Global Diabetes Devices and Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3447242/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:

Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin
Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry
Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019

Web Address:

http://www.researchandmarkets.com/reports/3447242/

Office Code:

SCISPV3N

Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:

USD 4795

Electronic (PDF) 1 - 5 Users:

USD 7795

Electronic (PDF) Enterprisewide:

USD 10795

Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:

Mr

Mrs

Dr

Miss
Last Name:

Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Ms

Prof

Page 1 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:

You will receive an email with a link to a secure webpage to enter your
credit card details.

Pay by check:

Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

Pay by wire transfer:

Please transfer funds to:
Account number

833 130 83

Sort code

98-53-30

Swift code

ULSBIE2D

IBAN number

IE78ULSB98533083313083

Bank Address

Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World

Sponsor Documents

Or use your account on DocShare.tips

Hide

Forgot your password?

Or register your new account on DocShare.tips

Hide

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close